Pharmacogenomics is the study of genes and how medications alter a person's reaction. Pharmacogenomics is a developing field of science that combines pharmacology, the study of pharmaceuticals, with genomics, the study of genes, to provide safe, effective dosages of medication that are matched to the unique genetic makeup of each patient. One of the key programmes in which scientists are discovering and learning how genes relate to the way the body reacts to drugs is the Human Genome Project. In the future, it will be possible to forecast a person's medicine effectiveness based on genetic makeup and investigate the existence of adverse drug reactions. Pharmacogenomics is still in its infancy despite advances in science and technology. Pharmacogenomics is only occasionally used, but new methods are continually being tested in clinical settings. Pharmacogenomics will soon make it possible to create treatments that are specifically tailored to treat conditions like neurological, cardiovascular, HIV, cancer, and asthma. Pharmacogenomics examines how a patient's genes may affect how they react to medications. Medicines can operate better or worse depending on genetic variations in a patient. Also, they can aid in identifying which patients will experience adverse effects, ranging from the merely uncomfortable to potentially fatal. Pharmacogenomics can assist doctors in determining the dosage and type of medications to administer to patients. In the overall population, a medicine may carry a minimal risk of side effects, but one group that carries a particular allele may carry a high risk (a variation in their genome). Abacavir, an antiviral drug used in HIV combination therapy, serves as an illustration of this. The majority of individuals tolerate abacavir well, but a small percentage (about 5%) can experience a hypersensitivity reaction, which can be serious and occasionally deadly. According to NICE guidelines, patients should be screened for the gene variant HLA-B*5701 before starting treatment since it significantly increases their likelihood of experiencing a hypersensitive reaction. Researchers have discovered that this test, which has been available for more than ten years, significantly affects the frequency of hypersensitive reactions. A patient may metabolise a medicine more quickly than usual, which causes it to leave the body more quickly and not have the desired effect. Or a drug may be metabolised slowly by a person, accumulating in their system to the point where it can be harmful. Thiopurines, a class of medications with uses in both chemotherapy and immunosuppression for autoimmune illnesses, serve as an illustration of this. They may have harmful negative effects if used in excessive doses. In addition to the risks they provide, they may necessitate pausing therapy, which could lower the likelihood that the chemotherapy will be effective. Thiopurines are processed by an enzyme called Thiopurine Methyltransferase (TPMT). A working copy of the TMTP gene is absent in about 3 out of every 1,000 individuals, and closer to 10% have a less active version of the gene than the majority of the population. Some patients might become quite unwell if they receive a typical course of treatment. NICE does not currently recommend a gene test, but encourages doctors to "consider evaluating TPMT activity before initiating azathioprine, mercaptopurine, or tioguanine therapy. Individuals without TPMT activity should not be treated with thiopurine medications; those with low TPMT activity can be treated with care. Clinicians caring for leukaemia patients should eventually have access to whole genome sequencing as it becomes available to patients with difficult-to-treat malignancies and seriously unwell youngsters.
0 Comments
Leave a Reply. |
Categories
All
|